Literature DB >> 9152596

Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.

E Mattiuz1, R Franklin, T Gillespie, A Murphy, J Bernstein, A Chiu, T Hotten, K Kassahun.   

Abstract

Olanzapine (OLZ) is a novel antipsychotic agent with a high affinity for serotonin (5-HT2), dopamine (D1/D2/D4), muscarinic (m1-m5), adrenergic (alpha 1), and histamine (H1) receptors. The pharmacokinetics, excretion, and metabolism of OLZ were studied in CD-1 mice, beagle dogs, and rhesus monkeys after a single oral and/or intravenous dose of [14C]OLZ. After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice. The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr). In mice and dogs, radioactivity was predominantly eliminated in feces; but, in monkeys, the major route of elimination of radioactivity was urine. Dogs and monkeys excreted in urine, respectively, 38% and 55% of the dose over a 168-hr period, whereas the fraction of the dose excreted in urine of mice over the collection period (120 hr) was 32%. OLZ was subject to substantial first-pass metabolism; at the tmax, OLZ accounted for 19%, 18%, and 8% of the radioactivity, in mice, dogs, and monkeys, respectively. The ratio of AUC OLZ to AUC radioactivity was, respectively, 10%, 14%, and 4% in mice, dogs, and monkeys. The principal urinary metabolites in mice were 7-hydroxy OLZ glucuronide, 2-hydroxymethyl OLZ, and 2-carboxy OLZ accounting for approximately 10%, 4%, and 2% of the dose. Metabolites that were present in urine in lesser amounts were 7-hydroxy OLZ, N-desmethyl OLZ, and N-desmethyl-2-hydroxymethyl OLZ. In dogs, the major metabolite accounting for approximately 8% of the dose was 7-hydroxy-N-oxide OLZ. Other metabolites identified were 2-hydroxymethyl OLZ, 2-carboxy OLZ, N-oxide OLZ, 7-hydroxy OLZ, and its glucuronide and N-desmethyl OLZ. The major metabolite in monkey urine was N-desmethyl-2-carboxy OLZ, and accounted for approximately 17% of the dose. In addition, N-oxide-2-hydroxymethyl, 2-carboxyl OLZ, and 2-hydroxymethyl OLZ were identified in monkey urine. Thus, in mice and dogs, OLZ was metabolized through aromatic hydroxylation, allylic oxidation, N-dealkylation, and N-oxidation reactions. In monkeys, OLZ was biotransformed mainly through double oxidation reactions involving the allylic carbon and methyl piperazine nitrogen. Whereas the oxidative metabolic profile of OLZ in animals was similar to that of humans, animals were notable for not forming appreciable amounts of the principal human metabolite (i.e. 10-N-glucuronide OLZ).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152596

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.

Authors:  R Coccurello; A Caprioli; O Ghirardi; R Conti; B Ciani; S Daniele; A Bartolomucci; A Moles
Journal:  Psychopharmacology (Berl)       Date:  2006-05-13       Impact factor: 4.530

2.  Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.

Authors:  Elodie M Girault; Bruno Guigas; Anneke Alkemade; Ewout Foppen; Mariëtte T Ackermans; Susanne E la Fleur; Eric Fliers; Andries Kalsbeek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-05       Impact factor: 3.000

3.  Chronic, constant-rate, gastric drug infusion in nontethered rhesus macaques (Macaca mulatta).

Authors:  Karen R Strait; Jack L Orkin; Daniel C Anderson; E Chris Muly
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-03       Impact factor: 1.232

Review 4.  Atypical neuroleptics in child and adolescent psychiatry.

Authors:  H Remschmidt; K Hennighausen; H W Clement; P Heiser; E Schulz
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 5.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

6.  The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.

Authors:  Li Li; Eun-Seon Yoo; Xiujuan Li; Steven C Wyler; Xiameng Chen; Rong Wan; Amanda G Arnold; Shari G Birnbaum; Lin Jia; Jong-Woo Sohn; Chen Liu
Journal:  J Exp Med       Date:  2021-05-12       Impact factor: 14.307

7.  Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

Authors:  Matthias van Woensel; Nathalie Wauthoz; Rémi Rosière; Karim Amighi; Véronique Mathieu; Florence Lefranc; Stefaan W van Gool; Steven de Vleeschouwer
Journal:  Cancers (Basel)       Date:  2013-08-14       Impact factor: 6.639

8.  Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex.

Authors:  Kari M Ersland; Silje Skrede; Christine Stansberg; Vidar M Steen
Journal:  Transl Psychiatry       Date:  2017-11-30       Impact factor: 6.222

9.  Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.

Authors:  Rizaldy C Zapata; Besma S Chaudry; Mariela Lopez Valencia; Dinghong Zhang; Scott A Ochsner; Neil J McKenna; Olivia Osborn
Journal:  Transl Psychiatry       Date:  2021-07-22       Impact factor: 6.222

10.  Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Authors:  John K Darby; David J Pasta; Michael G Wilson; John Herbert
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.